clinical trial · NCT05621811
Different Doses of Naronapride vs. Placebo in Gastroparesis
Dr. Falk Pharma GmbH·phase2·completed·n = 328
GastroparesisNaronapridePlacebo
brief summary
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.
started
Jan 3, 2023
primary completion
Aug 12, 2025
completion
Sep 4, 2025
last updated
Apr 15, 2026
official title
Double-blind, Randomised, Placebo-controlled, Dose-finding Phase IIb Trial to Evaluate the Efficacy, Safety, and Tolerability of a 12-week-treatment With Naronapride in Adult Participants With at Least Moderate Idiopathic or Diabetic Gastroparesis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol